Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.47 |
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8125697 | 0.98 | BCHE (0.47) | BCHEACHEMEN1NPC1GAA | |
| SCHEMBL843596 | 0.94 | BCHE (0.49) | BCHEACHEMEN1NPC1GAA | |
| SCHEMBL31037654 | 0.90 | MEN1 (0.46) | BCHEACHEMEN1NPC1GAA | |
| SCHEMBL212541 | 0.87 | EGFR (0.55) | BCHEMEN1NPC1GAARAB9A | |
| SCHEMBL29381474 | 0.87 | EGFR (0.55) | BCHEMEN1NPC1GAARAB9A | |
| SCHEMBL31337604 | 0.87 | BRD4 (0.44) | BCHEACHEBRD4 | |
| SCHEMBL22445116 | 0.87 | BRD4 (0.46) | BRD4 | |
| SCHEMBL17675518 | 0.86 | BCHE (0.48) | BCHEACHEMEN1KMT2A | |
| SCHEMBL17675516 | 0.86 | BCHE (0.48) | BCHEACHEMEN1KMT2A | |
| SCHEMBL212372 | 0.85 | EGFR (0.48) | MEN1NPC1GAARAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11547761-B1 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-01-10 | — | — | US | disclosed |
| US-11110178-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200206357-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-10675358-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-6069149-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | TERUMO KABUSHIKI KAISHA (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0894797-A1 | NOVEL AMIDE DERIVATIVES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF | TERUMO KABUSHIKI KAISHA (JP) | 1999-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206357-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | BCHE 474/4885ACHE 1269/4885MEN1 3653/4885 |
| US-10675358-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | BCHE 474/4885ACHE 1269/4885MEN1 3653/4885 |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | BCHE 546/4885ACHE 1268/4885MEN1 3734/4885 |
| US-11547761-B1 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | BCHE 474/4885ACHE 1269/4885MEN1 3653/4885 |
| US-11110178-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | BCHE 474/4885ACHE 1269/4885MEN1 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.